1282 related articles for article (PubMed ID: 32200663)
1. COVID-19 and Cardiovascular Disease.
Clerkin KJ; Fried JA; Raikhelkar J; Sayer G; Griffin JM; Masoumi A; Jain SS; Burkhoff D; Kumaraiah D; Rabbani L; Schwartz A; Uriel N
Circulation; 2020 May; 141(20):1648-1655. PubMed ID: 32200663
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 and the cardiovascular system.
Zheng YY; Ma YT; Zhang JY; Xie X
Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
[TBL] [Abstract][Full Text] [Related]
3. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.
Abassi Z; Assady S; Khoury EE; Heyman SN
Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1080-H1083. PubMed ID: 32223552
[No Abstract] [Full Text] [Related]
4. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
5. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
Lores E; Wysocki J; Batlle D
Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
[TBL] [Abstract][Full Text] [Related]
6. COVID-19: A Concern for Cardiovascular Disease Patients.
Sharma S
Cardiovasc Toxicol; 2020 Oct; 20(5):443-447. PubMed ID: 32729064
[TBL] [Abstract][Full Text] [Related]
7. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
9. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Sommerstein R; Kochen MM; Messerli FH; Gräni C
J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
[No Abstract] [Full Text] [Related]
10. The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.
Askin L; Tanrıverdi O; Askin HS
Arq Bras Cardiol; 2020 Jun; 114(5):817-822. PubMed ID: 32491073
[TBL] [Abstract][Full Text] [Related]
11. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
12. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler M; Esler D
J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
[No Abstract] [Full Text] [Related]
13. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
Roshanravan N; Ghaffari S; Hedayati M
Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
[TBL] [Abstract][Full Text] [Related]
16. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
17. The role of ACEIs/ARBs in COVID-19: Friend or foe?
Zhou Z; Qiu Y; Tao J
Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
[No Abstract] [Full Text] [Related]
18. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Sinha S; Sehgal A; Sehgal R
Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
[TBL] [Abstract][Full Text] [Related]
19. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
[TBL] [Abstract][Full Text] [Related]
20. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]